Thermo Fisher Scientific Inc. (NYSE:TMO) Stock Holdings Decreased by Annis Gardner Whiting Capital Advisors LLC

Annis Gardner Whiting Capital Advisors LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.4% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 799 shares of the medical research company’s stock after selling 20 shares during the quarter. Annis Gardner Whiting Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $424,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Frazier Financial Advisors LLC bought a new stake in Thermo Fisher Scientific in the fourth quarter worth approximately $49,000. Seven Mile Advisory bought a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $246,000. Journey Strategic Wealth LLC lifted its holdings in Thermo Fisher Scientific by 16.1% in the 4th quarter. Journey Strategic Wealth LLC now owns 1,929 shares of the medical research company’s stock worth $1,024,000 after purchasing an additional 268 shares during the last quarter. Aigen Investment Management LP grew its holdings in Thermo Fisher Scientific by 105.8% during the fourth quarter. Aigen Investment Management LP now owns 4,442 shares of the medical research company’s stock valued at $2,358,000 after purchasing an additional 2,284 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Thermo Fisher Scientific by 16.0% in the fourth quarter. Franklin Resources Inc. now owns 2,518,760 shares of the medical research company’s stock valued at $1,336,933,000 after purchasing an additional 347,560 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In related news, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the sale, the chief executive officer now owns 123,816 shares in the company, valued at $74,039,491.68. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,000 shares of company stock worth $18,486,980. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Trading Down 0.2 %

Shares of NYSE TMO traded down $1.08 during mid-day trading on Thursday, hitting $589.72. The company’s stock had a trading volume of 337,080 shares, compared to its average volume of 1,498,610. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33. The stock has a market cap of $225.11 billion, a price-to-earnings ratio of 37.90, a price-to-earnings-growth ratio of 2.75 and a beta of 0.80. The company’s fifty day simple moving average is $576.44 and its 200-day simple moving average is $545.71. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. The business had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be given a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.01%.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Raymond James boosted their price objective on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. JPMorgan Chase & Co. lifted their price target on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday, April 25th. Evercore ISI increased their price objective on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday, April 25th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.